Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29222920 | 0.82 | TSHR (0.46) | TDP1CYP3A4MAPTTSHRCACNA1B | |
| SCHEMBL7591076 | 0.81 | TDP1 (0.41) | TDP1CYP3A4MAPTTSHRCACNA1B | |
| SCHEMBL8975753 | 0.79 | TDP1 (0.43) | TDP1CYP3A4MAPTTSHRCACNA1B | |
| SCHEMBL8943666 | 0.76 | TSHR (0.57) | TDP1MAPTTSHRHPGDLMNA | |
| SCHEMBL4672425 | 0.74 | — | — | |
| SCHEMBL14745750 | 0.72 | CYP3A4 (0.45) | TDP1CYP3A4MAPTTSHRCACNA1B | |
| SCHEMBL11519762 | 0.71 | TDP1 (0.44) | TDP1CYP3A4MAPTTSHRCACNA1B | |
| SCHEMBL7036156 | 0.70 | CYP3A4 (0.43) | TDP1CYP3A4MAPTTSHRCACNA1B | |
| SCHEMBL167949 | 0.70 | CYP3A4 (0.43) | TDP1CYP3A4MAPTTSHRCACNA1B | |
| SCHEMBL4195585 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190142792-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2019-05-16 | — | — | US | claimed |
| US-20170035726-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2017-02-09 | — | — | US | claimed |
| US-20150011488-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2015-01-08 | — | — | US | claimed |
| US-20110218241-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2011-09-08 | — | — | US | claimed |
| US-20190142792-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2019-05-16 | — | — | US | disclosed |
| US-20170035726-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2017-02-09 | — | — | US | disclosed |
| US-20150011488-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2015-01-08 | — | — | US | disclosed |
| US-20110218241-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011488-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CUTA, OGG1, HAAO | TDP1 532/4885CYP3A4 4478/4885MAPT 1523/4885 |
| US-20170035726-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CUTA, OGG1, HAAO | TDP1 532/4885CYP3A4 4478/4885MAPT 1523/4885 |
| US-20110218241-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CUTA, OGG1, MGMT | TDP1 641/4885CYP3A4 4532/4885MAPT 1339/4885 |
| US-20190142792-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CUTA, OGG1, HAAO | TDP1 532/4885CYP3A4 4478/4885MAPT 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.